OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

ARGENX SE EO -,10/  NL0010832176  /

Stuttgart
2024-04-19  8:08:24 AM Chg. -10.700 Volume Bid10:00:01 PM Ask10:00:01 PM Market Capitalization Dividend Y. P/E Ratio
332.700EUR -3.12% 0
Turnover: 0.000		 -Bid Size: - -Ask Size: - 19.98 bill.EUR - -
GlobeNewswire 04-16 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire 03-27 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire 03-26 argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GlobeNewswire 03-26 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire 03-07 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire 02-29 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
GlobeNewswire 02-26 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 02-22 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...
GlobeNewswire 02-20 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...
GlobeNewswire 02-14 Genmab Publishes 2023 Annual Report
GlobeNewswire 01-18 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcu...
GlobeNewswire 01-08 argenx Highlights 2024 Strategic Priorities
GlobeNewswire 01-02 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2023-12-07 TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...
GlobeNewswire 2023-11-28 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocyt...
GlobeNewswire 2023-11-16 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Gene...
GlobeNewswire 2023-11-13 RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire 2023-11-09 X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
GlobeNewswire 2023-11-07 Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
GlobeNewswire 2023-11-01 RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
GlobeNewswire 2023-11-01 argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scie...
GlobeNewswire 2023-11-01 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 2023-10-31 argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 2023-10-24 argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
GlobeNewswire 2023-10-18 X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors